Home › Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C
 

Keywords :   


Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C

2014-04-10 13:18:10| Biotech - Topix.net

Gilead Sciences, Inc. today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir for the treatment of chronic hepatitis C virus infection.

Tags: c results treatment phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05IMDA launches annual IMDA Awards Competition
20.05Registration opens for FTAs Fall Technical Conference 2024
20.05Voting begins for Colored By INX Can Design Contest
20.05New Study Highlights Biodegradability of Cotton and Cellulosic Microfibers
20.05New ACA-Published Industry Market Analysis for the Paint & Coatings Industry Now Available
20.05Ulta Beauty Launches Same-Day Delivery with DoorDash
20.05Nivea Crmes Limited-Edition Pride Tin Heralds New Initiative with PFLAG
20.05Sheboygan Paint Company Appoints New Technical Sales Representative
More »